公开(公告)号：US5010107A

公开(公告)日：1991-04-23

申请号：US435543

申请日：1989-11-13

申请人： John P. Minton ,  Thomas E. Webb ,  Hussein M. Abou-Issa

发明人： John P. Minton ,  Thomas E. Webb ,  Hussein M. Abou-Issa

IPC分类号： A61K31/19

CPC分类号： A61K31/19

摘要： The present invention describes a protocol for achieving a very high degree of anticarcinogenic (or chemopreventive or cancer preventative) activity through the combination of a low suboptimal dose of a D-glucarolactone-based dietary anticarcinogen (i.e., calcium glucarate or CGT) with a low suboptimal dose of retinoid-based anticarcinogen (4-hydroxyphenyl retinamide or HPR). Since synergism is obtained by this combination, these two anticarcinogens can be employed at dosages far below toxic levels and at dosages that are practical as a food supplement.

摘要翻译： 本发明描述了通过将低次最低剂量的基于D-葡萄糖内酯的饮食抗癌药（即，葡萄糖酸钙或CGT）与低浓度的低葡萄糖酸（例如葡萄糖酸钙或CGT）的组合来实现非常高程度的致癌（或化学预防或癌症预防）活性的方案 次要剂量的类视黄醇类抗癌药（4-羟基苯基视黄酰胺或HPR）。 由于通过这种组合获得了协同作用，所以这两种抗癌剂可以以低于毒性水平的剂量和作为食品补充剂实用的剂量使用。

公开(公告)号：US4997852A

公开(公告)日：1991-03-05

申请号：US436049

申请日：1989-11-13

申请人： John P. Minton ,  Thomas E. Webb ,  Hussein M. Abou-Issa

发明人： John P. Minton ,  Thomas E. Webb ,  Hussein M. Abou-Issa

IPC分类号： A61K31/19

CPC分类号： A61K31/19

摘要： The present invention describes a protocol for achieving a very high degree of anticarcinogenic (chemopreventive and chemotherapeutic) activity through the combination of low suboptimal doses of a D-glucarolactone-based dietary anticarcinogen with low suboptimal doses of a retinoid-based anticarcinogen. Synergism is obtained by this combination and these two anticarcinogens can be employed at dosages far below toxic levels and at dosages that are practical as a food supplement.

摘要翻译： 本发明描述了通过低次要剂量的基于D-葡萄糖内酯的膳食抗癌药与低次优剂量的基于类视黄醇的抗癌药物的组合来实现非常高程度的致癌（化学预防和化学治疗）活性的方案。 通过这种组合获得协同作用，并且这两种抗癌剂可以以低于毒性水平的剂量和作为食物补充剂实用的剂量使用。

公开(公告)号：US4845123A

公开(公告)日：1989-07-04

申请号：US762339

申请日：1985-08-05

申请人： Zbigniew Walaszek ,  Malgorzata Hanausek-Walaszek ,  Thomas E. Webb ,  John P. Minton

发明人： Zbigniew Walaszek ,  Malgorzata Hanausek-Walaszek ,  Thomas E. Webb ,  John P. Minton

IPC分类号： A61K31/19 ,  A61K31/365

CPC分类号： A61K31/19 ,  A61K31/365

摘要： A method for the reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by inhibiting the activity of .beta.-glucuronidase in a mammal which comprises the administration to the mammal of an effective amount of a water insoluble, or sparingly soluble, sustained release precursor of glucarolactone or its analog is disclosed. The sustained release precursor of glucarolactone compound is selected from the group consisting of D-glucaric acid, D-galactaric acid, and L-idaric acid or derivatives or analogs. An orally administrable preparation of the sustained release precursor of glucarolactone compound is provided in the form of a capsule tablet, such that the glucarolactone or its analog is slowly released in the stomach of the treated animal or human.

摘要翻译： 一种通过抑制哺乳动物中β-葡糖醛酸糖苷酶的活性来减少内源和环境衍生化合物的不适当水平的方法，其包括向哺乳动物施用有效量的不溶于水的或微溶的持续的 公开了葡萄糖内酯或其类似物的释放前体。 葡萄糖内酯化合物的持续释放前体选自D-葡糖二酸，D-半乳糖酸，L-赖氨酸或其衍生物或类似物。 提供了可口服给药的葡萄糖内酯化合物的缓释前体，其形式为胶囊片剂，使得葡萄内酯酮或其类似物在经处理的动物或人的胃中缓慢释放。

公开(公告)号：US5008291A

公开(公告)日：1991-04-16

申请号：US436046

申请日：1989-11-13

申请人： John P. Minton ,  Thomas E. Webb ,  Hussein M. Abou-Issa

发明人： John P. Minton ,  Thomas E. Webb ,  Hussein M. Abou-Issa

IPC分类号： A61K31/19

CPC分类号： A61K31/19

摘要： The present invention describes a dietary supplement for achieving a very high degree of chemotherapeutic activity through the synergistic combination of a low suboptimal dose of a D-glucarolactone-based dietary anticarcinogen (calcium glucarate) with a low suboptimal dose of retinoid-based anticarcinogen (4-hydroxyphenyl retinamide).

摘要翻译： 本发明描述了通过低次优剂量的基于D-葡萄糖内酯的饮食抗癌药（葡糖二酸钙）与低次要剂量的基于类视黄醇的抗癌药（4）的协同组合来实现非常高程度的化疗活性的膳食补充剂 - 羟基苯基视黄酰胺）。